Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab with Ipilimumab or Nivolumab in Pancreatic and Colorectal Cancer
NCT03373188Phase 1Completed
- Sponsor
- Emory University
- Start
- Dec 2017
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pepinemab in pancreatic adenocarcinoma (PDAC) and colorectal adenocarcinoma (4 arms), sponsored by Emory University. Primary endpoint: Tumor CD8+ T cell infiltration up to 4 years. Started Dec 2017; status: completed.
02
Drugs
pepinemab
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT03373188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373188.